Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target
Open accessThe DOI matches its Crossref record; 82 of the 86 references it cites were found in a registry or an index.
Abstract
The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. In particular, critical roles of Grb7 in erythroblastic leukemia viral oncogene homolog (ERBB) family-mediated cancer development and malignancy have been intensively evaluated. The overexpression of Grb7 or the coamplification/cooverexpression of Grb7 and members of the ERBB family play essential roles in advanced human cancers and are associated with decreased survival and recurrence of cancers, emphasizing Grb7′s value as a prognostic marker and a therapeutic target. Peptide inhibitors of Grb7 are being tested in preclinical trials for their possible therapeutic effects. Here, we review the molecular, functional, and clinical aspects of Grb7 in ERBB family-mediated cancer development and malignancy with the aim to reveal alternative and effective therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GRB7 inhibition, either alone, in combination chemotherapy [39, 40], or in combination targeted therapy improves the efficiency of antitumor therapy.”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Lee, H., Volonté, D., Galbiati, F., Iyengar, P., Lublin, D. M., Bregman, D. B., Wilson, M. T., Campos‐González, R., Bouzahzah, B., Pestell, R. G., et al. (2000) · Molecular Endocrinology · doi:10.1210/me.14.11.1750 · Cited by 327
Pleckstrin homology domains and the cytoskeleton
Lemmon, M. A., Ferguson, K. M., & Abrams, C. S. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03243-4 · Cited by 262
Stein, D., Wu, J., Fuqua, S. A., Roonprapunt, C., Yajnik, V., D'Eustachio, P., Moskow, J. J., Buchberg, A. M., Osborne, C. K., & Margolis, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06386.x · Cited by 249
Emerging Roles of Focal Adhesion Kinase in Cancer
Tai, Y.-L., Chen, L.-C., & Shen, T.-L. (2015) · BioMed Research International · doi:10.1155/2015/690690 · Cited by 226
Self-citationAssociation of Focal Adhesion Kinase with Grb7 and Its Role in Cell Migration
Han, D. C., & Guan, J.-L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24425 · Cited by 225
Kauraniemi, P., Barlund, M. T., Monni, O. M., & Kallioniemi, A. H. (2001) · PubMed · Cited by 214
Identification of Tek/Tie2 Binding Partners
Jones, N., Master, Z., Jones, J., Bouchard, D., Gunji, Y., Sasaki, H., Daly, R., Alitalo, K., & Dumont, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30896 · Cited by 208
Targets of gene amplification and overexpression at 17q in gastric cancer.
Varis, A., Wolf, M., Monni, O. M., Vakkari, M.-L., Kokkola, A., Moskaluk, C., Frierson, H. F., Powell, S. M., Knuutila, S., Kallioniemi, A. H., et al. (2002) · PubMed · Cited by 177
Paik, S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-631 · Cited by 177
Han, D. C., Shen, T.-L., & Guan, J.-L. (2001) · Oncogene · doi:10.1038/sj.onc.1204775 · Cited by 170
Self-citationMargolis, B., Silvennoinen, O., Comoglio, F., Roonprapunt, C., Skolnik, E., Ullrich, A., & Schlessinger, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.8894 · Cited by 169
Priedigkeit, N., Hartmaier, R. J., Chen, Y., Vareslija, D., Basudan, A., Watters, R. J., Thomas, R., Leone, J. P., Lucas, P. C., Bhargava, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5630 · Cited by 166
He, W., Rose, D. W., Olefsky, J. M., & Gustafson, T. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.6860 · Cited by 134
Thömmes, K., Lennartsson, J., Carlberg, M., & Rönnstrand, L. (1999) · Biochemical Journal · doi:10.1042/bj3410211 · Cited by 126
Frantz, J. D., Giorgetti‐Peraldi, S., Ottinger, E. A., & Shoelson, S. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2659 · Cited by 122
Structural Basis for Inhibition of the Insulin Receptor by the Adaptor Protein Grb14
Depetris, R. S., Hu, J., Gimpelevich, I., Holt, L. J., Daly, R. J., & Hubbard, S. R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.001 · Cited by 117
Kao, J., & Pollack, J. R. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20339 · Cited by 113
Sahlberg, K. K., Hongisto, V., Edgren, H., Mäkelä, R., Hellström, K., Due, E. U., Vollan, H. K. M., Sahlberg, N., Wolf, M., Børresen‐Dale, A., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.012 · Cited by 112
Thömmes, K., Lennartsson, J., Carlberg, M., et al. (1999) · PubMed · Cited by 110
Mutations affecting embryonic cell migrations in Caenorhabditis elegans
Manser, J., & Wood, W. B. (1990) · Developmental Genetics · doi:10.1002/dvg.1020110107 · Cited by 108
Pandey, A., Liu, X., Dixon, J. E., Fiore, P. P. D., & Dixit, V. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10607 · Cited by 103
Han, D. C., Shen, T., & Guan, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001997200 · Cited by 103
Self-citationIdentification of the Rat Adapter Grb14 as an Inhibitor of Insulin Actions
Kasus-Jacobi, A., Perdereau, D., Auzan, C., Clauser, E., Van Obberghen, E., Mauvais-Jarvis, F., Girard, J., & Burnol, A.-F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.26026 · Cited by 101
Keegan, K. S., & Cooper, J. A. (1996) · PubMed · Cited by 96
Regulation of stress granule dynamics by Grb7 and FAK signalling pathway
Tsai, N., Ho, P., & Wei, L. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.19 · Cited by 95
Manser, J., Roonprapunt, C., & Margolis, B. (1997) · Developmental Biology · doi:10.1006/dbio.1997.8516 · Cited by 92
Tanaka, S., Mori, M., Akiyoshi, T., Tanaka, Y., Mafune, K., Wands, J. R., & Sugimachi, K. (1997) · PubMed · Cited by 91
Identification of Novel Non-phosphorylated Ligands, Which Bind Selectively to the SH2 Domain of Grb7
Pero, S. C., Oligino, L., Daly, R. J., Soden, A. L., Liu, C., Roller, P. P., Li, P., & Krag, D. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111816200 · Cited by 90
Fiddes, R. J., Campbell, D. H., Janes, P. W., Sivertsen, S. P., Sasaki, H., Wallasch, C., & Daly, R. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.13.7717 · Cited by 89
Specific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis
Tanaka, S., Pero, S. C., Taguchi, K., Shimada, M., Mori, M., Krag, D. N., & Arii, S. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj105 · Cited by 86
Chen, K., Liu, M. X., Mak, C. S. L., Yung, M. M. H., Leung, T. H., Xu, D., Ngu, S., Chan, K. K. L., Yang, H., Ngan, H., et al. (2017) · Theranostics · doi:10.7150/thno.22377 · Cited by 86
The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors
Stein, E. G., Gustafson, T. A., & Hubbard, S. R. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02282-7 · Cited by 85
EphB1 Associates with Grb7 and Regulates Cell Migration
Han, D. C., Shen, T., Miao, H., Wang, B., & Guan, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203165200 · Cited by 84
Self-citationGrb7 is a Downstream Signaling Component of Platelet-derived Growth Factor α- and β-Receptors
Yokote, K., Margolis, B., Heldin, C.-H., & Claesson-Welsh, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30942 · Cited by 82
Janes, P. W., Lackmann, M., Church, W. B., Sanderson, G. M., Sutherland, R. L., & Daly, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8490 · Cited by 81
Grb7 in intracellular signaling and its role in cell regulation
Shen, T.-L. (2004) · Frontiers in Bioscience · doi:10.2741/1229 · Cited by 81
Self-citationNadler, Y., González, A. M., Camp, R. L., Rimm, D. L., Kluger, H. M., & Kluger, Y. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp346 · Cited by 80
A novel variant of human Grb7 is associated with invasive esophageal carcinoma.
Tanaka, S., Mori, M., Akiyoshi, T., Tanaka, Y., Mafune, K.-I., Wands, J. R., & Sugimachi, K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2921 · Cited by 75
Pero, S. C., Shukla, G. S., Cookson, M. M., Flemer, S., & Krag, D. N. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603732 · Cited by 69
Chu, P.-Y., Huang, L.-Y., Hsu, C.-H., Liang, C.-C., Guan, J.-L., Hung, T.-H., & Shen, T.-L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018259 · Cited by 65
Self-citationGRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation
Bai, T., & Luoh, S.-W. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm221 · Cited by 62
GRB7 is required for triple-negative breast cancer cell invasion and survival
Giricz, O., Calvo, V., Pero, S. C., Krag, D. N., Sparano, J. A., & Kenny, P. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1822-6 · Cited by 62
Association of Grb7 with Phosphoinositides and Its Role in the Regulation of Cell Migration
Shen, T.-L., Han, D. C., & Guan, J.-L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203085200 · Cited by 57
Self-citationKasus‐Jacobi, A., Béréziat, V., Perdereau, D., Girard, J. R., & Burnol, A. (2000) · Oncogene · doi:10.1038/sj.onc.1203469 · Cited by 52
Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
Chan, D. W., Hui, W. W. Y., Cai, P. C. H., Liu, M. X., Yung, M. M. H., Mak, C. S. L., Leung, T. H. Y., Chan, K. K. L., & Ngan, H. Y. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052578 · Cited by 51 · cited 4×
“Consistently, inhibition of the specific kinase activity of Grb7-mediated downstream signals significantly reduces Grb7-mediated cancer invasion [59].”
BackgroundInfluentialSyk Is Recruited to Stress Granules and Promotes Their Clearance through Autophagy
Krisenko, M. O., Higgins, R. L., Ghosh, S., Zhou, Q., Trybula, J. S., Wang, W.-H., & Geahlen, R. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.642900 · Cited by 51
Chu, P.-Y., Li, T.-K., Ding, S.-T., Lai, I.-R., & Shen, T.-L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.114124 · Cited by 51
Self-citationGRB7 protein over-expression and clinical outcome in breast cancer
Ramsey, B., Bai, T., Newell, A. H., Troxell, M. L., Park, B. S., Olson, S. B., Keenan, E. J., & Luoh, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1010-0 · Cited by 50
Wojcik, J., Girault, J., Labesse, G., Chomilier, J., Mornon, J., & Callebaut, I. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0727 · Cited by 49
Pradip, D., Bouzyk, M., Dey, N., & Leyland-Jones, B. R. (2013) · Europe PMC (PubMed Central) · Cited by 49
Porter, C. J., Matthews, J. M., Mackay, J. P., Pursglove, S. E., Schmidberger, J. W., Leedman, P. J., Pero, S. C., Krag, D. N., Wilce, M. C., & Wilce, J. A. (2007) · BMC Structural Biology · doi:10.1186/1472-6807-7-58 · Cited by 44
Walch, A. K., Specht, K., Braselmann, H., Stein, H. J., Siewert, J. R., Hopt, U. T., Höfler, H., & Werner, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20411 · Cited by 44
Tsai, N.-P., Lin, Y.-L., Tsui, Y.-C., & Wei, L.-N. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910083 · Cited by 43 · cited 2×
“In response to EGF stimulation, nuclear SHP-2-mediated dephosphorylated nuclear Grb7 recruits KOR mRNA and Hu antigen R, subsequently leading to the nuclear export of KOR mRNA [45].”
BackgroundWang, Y., Chan, D. W., Liu, V. W. S., Chiu, P., & Ngan, H. Y. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0018 · Cited by 41
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin, W. W., Yergiyev, O., Bunker, M. L., Silverman, J. F., & Krishnamurti, U. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000349 · Cited by 40
Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer
Kwon, M. J., Kim, R. N., Song, K., Jeon, S., Jeong, H. M., Kim, J. S., Han, J., Hong, S., Oh, E., Choi, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21150 · Cited by 34
Watson, G. M., Kulkarni, K., Sang, J., Ma, X., Gunzburg, M. J., Perlmutter, P., Wilce, M. C. J., & Wilce, M. C. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01320 · Cited by 31
Li, H., Sánchez-Torres, J., del CARPIO, A., Nogales, A., Molina-Ortíz, P., Moreno, M., Török, K., & Villalobo, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208591 · Cited by 30
Expression screening of 17q12–21 amplicon reveals GRB7 as an ERBB2‐dependent oncogene
Saito, M., Kato, Y. H., Ito, E., Fujimoto, J., Ishikawa, K., Doi, A., Kumazawa, K., Matsui, A., Takebe, S., Ishida, T., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.05.003 · Cited by 30
Haran, M. Z., Chebatco, S., Flaishon, L., Lantner, F., Harpaz, N., Valinsky, L. J., Berrébi, A., & Shachar, I. (2004) · Leukemia · doi:10.1038/sj.leu.2403512 · Cited by 30
Genomic Organization and Control of the Grb7 Gene Family
Lucas-Fernandez, E., García‐Palmero, I., & Villalobo, A. (2008) · Current Genomics · doi:10.2174/138920208783884847 · Cited by 28
Wang, Z., Wang, M., & Carr, B. I. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200006)183:3<381::aid-jcp11>3.0.co;2-o · Cited by 27
Watson, G. M., Kulkarni, K., Brandt, R., Borgo, M. P. D., Aguilar, M., & Wilce, M. C. J. (2017) · ACS Omega · doi:10.1021/acsomega.6b00561 · Cited by 27
Grb7-SH2 domain dimerisation is affected by a single point mutation
Porter, C. J., Wilce, M. C. J., Mackay, J. P., Leedman, P. J., & Wilce, J. A. (2005) · European Biophysics Journal · doi:10.1007/s00249-005-0480-1 · Cited by 25
Sparano, J. A., Goldstein, L. J., Childs, B. H., Shak, S., Brassard, D., Badve, S., Baehner, F. L., Bugarini, R., Rowley, S., Perez, E. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3357 · Cited by 22 · cited 4×
“4% in the low and the high GRB7 RNA expression groups, respectively [69].”
BackgroundInfluentialContext-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines
Lim, R. C. C., Price, J. T., & Wilce, M. C. J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2838-5 · Cited by 22
Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7
Gunzburg, M. J., Kulkarni, K., Watson, G. M., Ambaye, N. D., Borgo, M. P. D., Brandt, R., Pero, S. C., Perlmutter, P., Wilce, M. C. J., & Wilce, J. A. (2016) · Scientific Reports · doi:10.1038/srep27060 · Cited by 21
Siamakpour‐Reihani, S., Argiros, H. J., Wilmeth, L. J., Haas, L. L., Peterson, T. A., Johnson, D. L., Shuster, C. B., & Lyons, B. A. (2008) · Journal of Molecular Recognition · doi:10.1002/jmr.916 · Cited by 19
Zhao, H., Zhang, X., Jia, X., & Wang, H.-B. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.05.013 · Cited by 18
Uptake of a cell permeable G7‐18NATE construct into cells and binding with the Grb7‐SH2 domain
Ambaye, N. D., Lim, R. C. C., Clayton, D., Gunzburg, M. J., Price, J. T., Pero, S. C., Krag, D. N., Wilce, M. C. J., Aguilar, M., Perlmutter, P., et al. (2010) · Biopolymers · doi:10.1002/bip.21403 · Cited by 18
Calmodulin regulates the translocation of Grb7 into the nucleus
García‐Palmero, I., & Villalobo, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.017 · Cited by 17
Grb7 and Filamin‐a associate and are colocalized to cell membrane ruffles upon EGF stimulation
Paudyal, P., Shrestha, S., Madanayake, T. W., Shuster, C. B., Rohrschneider, L. R., Rowland, A. M., & Lyons, B. A. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2297 · Cited by 17
Siamakpour‐Reihani, S., Peterson, T. A., Bradford, A. M., Argiros, H. J., Haas, L. L., Lor, S. N., Haulsee, Z. M., Spuches, A. M., Johnson, D. L., Rohrschneider, L. R., et al. (2010) · Journal of Molecular Recognition · doi:10.1002/jmr.1062 · Cited by 16
Grb7 Protein Stability Modulated by Pin1 in Association with Cell Cycle Progression
Tai, Y.-L., Tung, L.-H., Lin, Y., Lu, P., Chu, P.-Y., Wang, M.-Y., Huang, W., Chen, K., Lee, H., & Shen, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163617 · Cited by 15
Self-citationLuoh, S., Wagoner, W., Wang, X., Hu, Z., Lai, X., Chin, K., Sears, R. C., & Ramsey, E. E. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.22963 · Cited by 14
Design and testing of bicyclic inhibitors of Grb7—are two cycles better than one?
Gunzburg, M. J., Ambaye, N. D., Borgo, M. P. D., Perlmutter, P., & Wilce, M. C. J. (2013) · Biopolymers · doi:10.1002/bip.22237 · Cited by 12
Qian, L., Bradford, A. M., Cooke, P. H., & Lyons, B. A. (2016) · Journal of Molecular Recognition · doi:10.1002/jmr.2533 · Cited by 11
Dimerization in the Grb7 Protein
Peterson, T. A., Benallie, R. L., Bradford, A. M., Pias, S. C., Yazzie, J., Lor, S. N., Haulsee, Z. M., Park, C. K., Johnson, D. L., Rohrschneider, L. R., et al. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2205 · Cited by 10
Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target
Watson, G. M., Lucas, W. A. H., Gunzburg, M. J., & Wilce, M. C. J. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00064 · Cited by 9
Research works printed but not linked: 1
- Tanaka, 2000, Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma, J. Cell Physiol., 183, 411, 10.1002/(sici)1097-4652(200006)183:3<411::aid-jcp14>3.0.co;2-z · DOI · Paper page
Cited by
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Ling, Y., Liang, G., Lin, Q., Fang, X., Luo, Q., Cen, Y., Mehrpour, M., Hamaï, A., Liu, Z., Shi, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01476-7 · Cited by 101
Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?
Alshamrani, A. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01084 · Cited by 92
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Biomedicines · doi:10.3390/biomedicines9111512 · Cited by 93
Yu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02077-w · Cited by 70
“GRB7 inhibition, either alone, in combination chemotherapy [39, 40], or in combination targeted therapy improves the efficiency of antitumor therapy.”
BackgroundPeptide-Based Strategies for Targeted Tumor Treatment and Imaging
Ayo, A., & Laakkonen, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040481 · Cited by 71
Metadata
- Authors
- Chu, P.-Y., Tai, Y.-L., & Shen, T.-L.
- Affiliations
- National Taiwan University (TW)
- Corresponding author
- Shen, Tang-Long
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-05-10
- Volume
- 8
- Issue
- 5
- Pages
- 435
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6562560
- OpenAlex
- W2944451168
- Cited by
- 84
- References
- 86
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 13 · 2023: 9 · 2022: 34 · 2021: 9 · 2020: 3 · 2019: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (105‐2320‐B‐002‐058‐MY3, 106‐2911‐I‐002‐569)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- Grb7, epidermal growth factor receptor, ErbB family, adaptor proteins, carcinogenesis, prognostic factors, therapeutic target, peptide inhibitors, tumor recurrence, signaling pathways
- MeSH terms
- Humans, Neoplasms, Biomarkers, Tumor, Signal Transduction, GRB7 Adaptor Protein, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.